secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2025-10-17T23:59:59+00:00
Accession:  0001193125-25-241968
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics appoints Katina Dorton to board; Mardi Dier resigns
------------------------------------------------------------------------

- Mardi Dier resigned as Class III director effective Oct 17, 2025, not due to any disagreement.
- Katina Dorton, J.D., MBA, appointed as Class III director and Audit Committee Chair, effective Oct 17.
- Dorton brings 30+ years of healthcare finance and board experience; served as CFO at NodThera.
- Dorton received option to purchase 76,000 shares vesting over 3 years under 2020 Equity Incentive Plan.
- Dorton also serves on boards of Fulcrum Therapeutics (FULC) and TScan Therapeutics (TCRX).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000119312525241968/0001193125-25-241968-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000119312525241968/prld-20251015.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-241968

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer